Cart
sales@molnova.com
Lenalidomide-Br
CAS No. 2093387-36-9
Lenalidomide-Br ( —— )
Catalog No. M23940 CAS No. 2093387-36-9
Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLenalidomide-Br
-
NoteResearch use only, not for human use.
-
Brief DescriptionLenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.
-
DescriptionLenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC STAT3 degrader SD-36[1][2].
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorCereblon
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2093387-36-9
-
Formula Weight323.1
-
Molecular FormulaC13H11BrN2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 30 mg/mL (92.84 mM; Need ultrasonic)
-
SMILESO=C(C(N(CC1=C2C=CC=C1Br)C2=O)CC3)NC3=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bai L, et al. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019 Nov 11;36(5):498-511.e17.
molnova catalog
related products
-
Boc-Val-Cit-PAB-PNP
Boc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
-
MT-802
MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM).
-
TL13-12
TL13-12 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of TAE684 and the cereblon ligand pomalidomide.
